Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Surgery
Published in: Indian Journal of Surgery 5/2015

01-10-2015 | Original Article

Pancreatic Cancer: a Challenge to Cure

Author: M. Tewari

Published in: Indian Journal of Surgery | Issue 5/2015

Login to get access

Abstract

Pancreatic ductal adenocarcinoma (PDA) is a challenging disease, as overall survival has not improved over the last several decades. The disease is characterized by late diagnosis, difficult major surgery in resectable patients, and a biologically chemoresistant tumor. Intense research in the field is ongoing to develop biomarkers for early detection and prognostication. Surgery is presently the crux of the management of PDA and has been standardized over the years with high-volume centers reporting <5 % operative mortality. The biggest problem is to overcome the inherent chemoresistance of the tumor that is densely fibrotic and hypoxic and has a tendency to invade surrounding neuronal plexuses. This review attempts to summarize in brief the reasons why PDA is difficult to treat, and provides a glimpse of the ongoing research in the field.
Literature
1.
2.
3.
Kawai M, Yamaue H (2010) Analysis of clinical trials evaluating complications after pancreaticoduodenectomy: a new era of pancreatic surgery. Surg Today 40:1011–1017PubMedCrossRef
4.
Winter JW, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J et al (2006) 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 10:1199–1211PubMedCrossRef
5.
6.
Hruban RH, Adsay NV, Albores-Saavedra J et al (2001) Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 25:579–586PubMedCrossRef
7.
Clores MJ, Thosani A, Buscaglia JM (2014) Multidisciplinary diagnostic and therapeutic approaches to pancreatic cystic lesions. J Multidiscip Healthc 7:81–91PubMedPubMedCentral
8.
Yachida S, Jones S, Bozic I, Antal T et al (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467(7319):1114–1117PubMedPubMedCentralCrossRef
9.
10.
Shi C, Hruban RH, Klein AP (2009) Familial pancreatic cancer. Arch Pathol Lab Med 133:365–374PubMed
11.
Klein AP, Brune KA, Petersen GM et al (2004) Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64:2634–2638PubMedCrossRef
12.
van der Heijden MS, Brody JR, Dezentje DA et al (2005) In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 11:7508–7515PubMedCrossRef
13.
Winder JM, Yeo CJ, Broody JR (2013) Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol 107:15–22CrossRef
14.
Tempero MA, Uchida E, Takasaki H et al (1987) Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 47:5501–5503PubMed
15.
Marrelli D, Caruso S, Pedrazzani C et al (2009) CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg 198:333–339PubMedCrossRef
16.
Ballehaninna UK, Chamberlain RS (2012) The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol 3:105–119PubMedPubMedCentral
17.
Parikh DA, Durbin-Johnson B, Urayama S (2014) Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population. J Gastrointest Cancer 45(1):74–79PubMedPubMedCentralCrossRef
18.
O’Brien DP, Sandanayake NS, Jenkinson C et al (2015) Serum CA19-9 is significantly up-regulated up to 2 years prior to diagnosis with pancreatic cancer: implications for early disease detection. Clin Cancer Res 21(3):622–631PubMedPubMedCentralCrossRef
19.
Hwang TL, Liang Y, Chien KY et al (2006) Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma. Proteomics 6:2259–2272PubMedCrossRef
20.
Patwa TH, Li C, Poisson LM et al (2009) The identification of phosphoglycerate kinase-1 and histone H4 autoantibodies in pancreatic cancer patient serum using a natural protein microarray. Electrophoresis 30:2215–2226PubMedPubMedCentralCrossRef
21.
Guo J, Wang W, Liao P et al (2009) Identification of serum biomarkers for pancreatic adenocarcinoma by proteomic analysis. Cancer Sci 100:2292–2301PubMedCrossRef
22.
Rong Y, Jin D, Hou C et al (2010) Proteomics analysis of serum protein profiling in pancreatic cancer patients by DIGE: up-regulation of mannose-binding lectin 2 and myosin light chain kinase 2. BMC Gastroenterol 10:68PubMedPubMedCentralCrossRef
23.
Xue A, Scarlett CJ, Chung L et al (2010) Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis. Br J Cancer 103:391–400PubMedPubMedCentralCrossRef
24.
OuYang D, Xu J, Huang H, Chen Z (2011) Metabolomic profiling of serum from human pancreatic cancer patients using 1H NMR spectroscopy and principal component analysis. Appl Biochem Biotechnol 165(1):148–154PubMedCrossRef
25.
Napoli C, Sperandio N, Lawlor RT et al (2012) Urine metabolic signature of pancreatic ductal adenocarcinoma by (1)h nuclear magnetic resonance: identification, mapping, and evolution. J Proteome Res 11(2):1274–1283PubMedCrossRef
26.
Davis VW, Schiller DE, Eurich D, Bathe OF, Sawyer MB (2013) Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature. Ann Surg Oncol 20(Suppl 3):S415–S423PubMedCrossRef
27.
Gowda GA (2010) Human bile as a rich source of biomarkers for hepatopancreatobiliary cancers. Biomark Med 4(2):299–314PubMedCrossRef
28.
Schultz NA, Dehlendorff C, Jensen BV et al (2014) MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA 311(4):392–404PubMedCrossRef
29.
Jones S, Zhang X, Parsons DW et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–1806PubMedPubMedCentralCrossRef
30.
Chiorean EG, Coveler AL (2015) Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther 9:3529–3545PubMedPubMedCentralCrossRef
31.
Shi C, Fukushima N, Abe T et al (2008) Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. Cancer Biol Ther 7:353–360PubMedCrossRef
32.
Winter JM, Tang LH, Klimstra DS et al (2012) A novel survival- based tissue microarray of pancreatic cancer identifies clinical useful candidate biomarkers. PLoS One 7(7), e40157. doi:10.​1371/​journal.​pone.​0040157
33.
Koops A, Wojciechowski B, Broering DC, Adam G, Krupski- Berdien G (2004) Anatomic variations of the hepatic arteries in 604 selective celiac and superior mesenteric angiographies. Surg Radiol Anat 26:239–244PubMedCrossRef
34.
Balachandran A, Darden DL, Tamm EP, Faria SC, Evans DB, Charnsangavej C (2008) Arterial variants in pancreatic adenocarcinoma. Abdom Imaging 33(2):214–221PubMedCrossRef
35.
Perwaiz A, Singh A, Singh T, Chaudhary A (2010) Incidence and management of arterial anomalies in patients undergoing pancreaticoduodenectomy. JOP 11(1):25–30 (Online) PubMed
36.
Kimura W, Watanabe T (2011) Anatomy of the pancreatic nerve plexuses and significance of their dissection. Nihon Geka Gakkai Zasshi 112(3):170–176PubMed
37.
Ceyhan GO, Demir IE, Altintas B et al (2008) Neural invasion in pancreatic cancer: a mutual tropism between neurons and cancer cells. Biochem Biophys Res Commun 374:442–447PubMedCrossRef
38.
Kayahara M, Nakagawara H, Kitagawa H, Ohta T (2007) The nature of neural invasion by pancreatic cancer. Pancreas 35:218–223PubMedCrossRef
39.
40.
Takahashi T, Ishikura H, Motohara T et al (1997) Perineural invasion by ductal adenocarcinoma of the pancreas. J Surg Oncol 65:164–170PubMedCrossRef
41.
Gulbinas A, Barauskas G, Pundzius J (2004) Pancreaticojejunal anastomosis: the “Achilles heel” of pancreaticoduodenectomy. Medicina (Kaunas) 40:927–934
42.
Tewari M, Hazrah P, Kumar V, Shukla HS (2010) Options of restorative pancreaticoenteric anastomosis following pancreaticoduodenectomy: a review. Surg Oncol 19(1):17–26PubMedCrossRef
43.
Birkmeyer JD, Siewers JE, Finlayson EVA et al (2002) Hospital volume and hospital mortality in the United States. N Engl J Med 346:1128–1137PubMedCrossRef
44.
Wang Z, Li Y, Ahmad A et al (2011) Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 8:27–33PubMedCrossRef
45.
Zalatnai A, Molnar J (2007) Review. Molecular background of chemoresistance in pancreatic cancer. In Vivo 21:339–347PubMed
46.
Erkan M, Hausmann S, Michalski CW et al (2012) The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol 9(8):454–467PubMedCrossRef
47.
Neesse A, Michl P, Frese KK et al (2011) Stromal biology and therapy in pancreatic cancer. Gut 60(6):861–868PubMedCrossRef
48.
Wormann SM, Diakopoulos KN, Lesina M, Algul H (2014) The immune network in pancreatic cancer development and progression. Oncogene 33(23):2956–2967PubMedCrossRef
49.
50.
Demir IE, Ceyhan GO, Rauch U et al (2010) The microenvironment in chronic pancreatitis and pancreatic cancer induces neuronal plasticity. Neurogastroenterol Motil 22(480–490):e112–e483
51.
Michl P, Gress TM (2012) Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid. Gut 61(10):1377–1379PubMedCrossRef
52.
Koong AC, Mehta VK, Le QT, Fisher GA et al (2000) Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 48(4):919–922PubMedCrossRef
53.
Komar G, Kauhanen S, Liukko K et al (2009) Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin Cancer Res 15(17):5511–5517PubMedCrossRef
54.
Olive KP, Jacobetz MA, Davidson CJ et al (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324(5933):1457–1461PubMedPubMedCentralCrossRef
55.
Stephenson J, Wolpin BM, Becerra C et al (2011) The safety of IPI-926, a novel hedgehog pathway inhibitor, in combination with gemcitabine in patients (pts) with metastatic pancreatic cancer. J Clin Oncol 29(Suppl):4114
56.
Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703CrossRef
57.
Goldstein D, El-Maraghi RH, Hammel P et al (2014) Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC) [abstract]. ASCO Meet Abstr 32:4027
58.
Von Hoff DD, Ramanathan RK, Borad MJ et al (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 29(34):4548–4554CrossRef
59.
Neesse A, Frese KK, Chan DS et al (2014) SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut 63(6):974–983PubMedPubMedCentralCrossRef
60.
Frese K, Neesse A, Cook N et al (2012) nab-paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov 2:260–269PubMedCrossRef
61.
Fattahi R, Balci N, Perman W et al (2009) Pancreatic diffusion-weighted imaging (DWI): comparison between mass-forming focal pancreatitis (FP), pancreatic cancer (PC), and normal pancreas. J Magn Reson Imaging 29:350–356PubMedCrossRef
62.
Yao X, Zeng M, Wang H et al (2012) Evaluation of pancreatic cancer by multiple breath-hold dynamic contrast-enhanced magnetic resonance imaging at 3.0T. Eur J Radiol 81:e917–e922PubMedCrossRef
63.
D’Onofrio M, Zamboni G, Malago R et al (2009) Resectable pancreatic adenocarcinoma: is the enhancement pattern at contrast-enhanced ultrasonography a pre-operative prognostic factor? Ultrasound Med Biol 35:1929–1937PubMedCrossRef
64.
Opačić D, Rustemović N, Kalauz M et al (2015) Endoscopic ultrasound elastography strain histograms in the evaluation of patients with pancreatic masses. World J Gastroenterol 21(13):4014–4019PubMedPubMedCentralCrossRef
65.
66.
Patel M, Gomes A, Ruderman S et al (2014) Polarization gating spectroscopy of normal-appearing duodenal mucosa to detect pancreatic cancer. Gastrointest Endosc 80(5):786–93.e1-2PubMedPubMedCentralCrossRef
67.
Le DT, Wang-Gillam A, Picozzi V et al (2015) Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol 33(12):1325–1333PubMedCrossRef
Metadata
Title
Pancreatic Cancer: a Challenge to Cure
Author
M. Tewari
Publication date
01-10-2015
Publisher
Springer India
Published in
Indian Journal of Surgery / Issue 5/2015
Print ISSN: 0972-2068
Electronic ISSN: 0973-9793
DOI
https://doi.org/10.1007/s12262-015-1369-6

Other articles of this Issue 5/2015

Indian Journal of Surgery 5/2015 Go to the issue

Original Article

Adjuvant/Perioperative Therapy in Pancreatic and Periampullary Cancer

Commentary

Cystic Lesions of the Pancreas: Observe or Operate

Original Article

Improving Survival of Pancreatic Cancer. What Have We Learnt?

Original Article

Surgical Management of Chronic Pancreatitis

Editorial

Can Making of a Surgeon be a Spiritual Pursuit?

Original Article

Surgery for Pancreatic and Periampullary Carcinoma